Other

Accrued sales returns

Moderna Accrued sales returns decreased by 7.7% to $470.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 39.5%, from $337.00M to $470.00M.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2022
Last reportedQ1 2026May 1, 2026
Metric ID: other_contract_with_customer_refund_liability

Historical Data

12 periods
 Q4 '22Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0.00$184.00M$556.00M$574.00M$554.00M$403.00M$370.00M$337.00M$308.00M$426.00M$509.00M$470.00M
QoQ Change+202.2%+3.2%-3.5%-27.3%-8.2%-8.9%-8.6%+38.3%+19.5%-7.7%
YoY Change+119.0%-33.5%-41.3%-44.4%+5.7%+37.6%+39.5%
Range$0.00$574.00M
Avg YoY Growth+11.8%
Median YoY Growth+5.7%

Product Breakdown

View all
SegmentQ3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '25
Net product sales$184.00M$556.00M$574.00M$554.00M$403.00M$509.00M
Total$184.00M$556.00M$574.00M$554.00M$403.00M$509.00M

Frequently Asked Questions

What is Moderna's accrued sales returns?
Moderna (MRNA) reported accrued sales returns of $470.00M in Q1 2026.
How has Moderna's accrued sales returns changed year-over-year?
Moderna's accrued sales returns increased by 39.5% year-over-year, from $337.00M to $470.00M.